Table of Contents page: European Journal of Cancer

Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Pembrolizumab in combination with nab-paclitaxel for the treatment of patients with early-stage triple-negative breast cancer – A single-arm phase II trial (NeoImmunoboost, AGO-B-041)

Peter A. Fasching,
Alexander Hein,
Hans-Christian Kolberg,
...
Sara Y. Brucker,
Andreas D. Hartkopf,
Michael Untch

Published online: January 24, 2023

p1-9

Open Access

OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

Mark E. Robson,
Seock-Ah Im,
Elzbieta Senkus,
...
Anitra Fielding,
Allison Allen,
Pierfranco Conte

Published online: February 14, 2023

p39-47

Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial

Frankie A. Holmes,
Beverly Moy,
Suzette Delaloge,
...
Miguel Martin,
Arlene Chan
for the ExteNET Study Group

Published online: February 09, 2023

p48-59

Open Access

Clinical efficacy of fulvestrant versus exemestane as first-line therapies for Chinese postmenopausal oestrogen-receptor positive /human epidermal growth factor receptor 2 -advanced breast cancer (FRIEND study)

Jiayu Wang,
Li Cai,
Yanqiu Song,
...
Jifeng Feng,
Xiaojia Wang,
Binghe Xu

Published online: February 14, 2023

p73-82

Open Access

Multicentre real-world data of ramucirumab plus docetaxel after combined platinum-based chemotherapy with programmed death-1 blockade in advanced non-small cell lung cancer: NEJ051 (REACTIVE study)

Atsushi Nakamura,
Ou Yamaguchi,
Keita Mori,
...
Hiroaki Kodama,
Kunihiko Kobayashi,
Kyoichi Kaira

Published online: February 10, 2023

p62-72

Adjuvant durvalumab after concurrent chemoradiotherapy for patients with unresectable stage III NSCLC harbouring uncommon genomic alterations

Francesco Cortiula,
Dirk De Ruysscher,
Michelle Steens,
...
Anthonie van der Wekken,
Martina Alberti,
Lizza E.L. Hendriks

Published online: February 21, 2023

p172-178

Open Access

Soluble programmed cell death ligand 1 predicts prognosis for gastric cancer patients treated with nivolumab: Blood-based biomarker analysis for the DELIVER trial

Hisato Kawakami,
Yu Sunakawa,
Eisuke Inoue,
...
Kazuhiko Nakagawa,
Wataru Ichikawa,
Masashi Fujii

Published online: February 09, 2023

p10-20

Primary tumour side as a driver for treatment choice in RAS wild-type metastatic colorectal cancer patients: a systematic review and pooled analysis of randomised trials

Daniele Rossini,
Alessandra Boccaccino,
Martina Carullo,
...
Roberto Moretto,
Gianluca Masi,
Chiara Cremolini

Published online: February 17, 2023

p106-116

Clinical and exploratory biomarker findings from the MODUL trial (Cohorts 1, 3 and 4) of biomarker-driven maintenance therapy for metastatic colorectal cancer

Michel Ducreux,
Josep Tabernero,
Axel Grothey,
...
Hans-Joachim Schmoll,
Eric Van Cutsem,
Aimery de Gramont

Published online: February 03, 2023

p137-150

Open Access

Proton pump inhibitors and antibiotics adversely effect the efficacy of nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

Akihisa Wada,
Tomohiro Enokida,
Susumu Okano,
...
Naohiro Takeshita,
Nobukazu Tanaka,
Makoto Tahara

Published online: February 14, 2023

p30-38

Impact of immune checkpoint inhibitors and targeted therapy on health-related quality of life of people with stage III and IV melanoma: a mixed-methods systematic review

Julia Lai-Kwon,
Andrisha-Jade Inderjeeth,
Karolina Lisy,
Shahneen Sandhu,
Claudia Rutherford,
Michael Jefford

Published online: February 17, 2023

p83-105

Faecal haemoglobin concentration predicts all-cause mortality

Ulrik Deding,
Lasse Kaalby,
Robert Steele,
...
Jonna S. Madsen,
Thomas Bjørsum-Meyer,
Gunnar Baatrup

Published online: February 14, 2023

p21-29

Open Access

Immunogenetic variations predict immune-related adverse events for PD-1/PD-L1 inhibitors

Zhaodan Xin,
Liting You,
Feifei Na,
...
Jie Chen,
Juan Zhou,
Binwu Ying

Published online: February 22, 2023

p124-136

Open Access

Survival and immunotoxicities in association with sex-specific body composition patterns of cancer patients undergoing immune-checkpoint inhibitor therapy – A systematic review and meta-analysis

Paul Trinkner,
Sophie Günther,
Ina Monsef,
...
Michael von Bergwelt-Baildon,
David M. Cordas dos Santos,
Sebastian Theurich

Published online: February 17, 2023

p151-171

Biomarkers of response to immunotherapy in early stage non-small cell lung cancer

Matthieu Roulleaux Dugage,
Víctor Albarrán-Artahona,
Juan Carlos Laguna,
...
Benjamin Besse,
Laura Mezquita,
Edouard Auclin

Published online: February 17, 2023

p179-196

Letter Re: Metabolic switch in cancer – Survival of the fittest

Chen-Xiong Hsu,
Pei-Wei Shueng

Published online: February 20, 2023

p60-61

The response rate by tumour type for tissue-agnostic approved drugs

Alyson Haslam,
Vinay Prasad

Published online: February 14, 2023

p117-119

eIF4F translation initiation complex, a predictive marker of response to immunotherapy in mucosal melanoma

Antoine Moya-Plana,
Carine Ngo,
Emilie Lanoy,
Stephan Vagner,
Caroline Robert

Published online: February 15, 2023

p120-123

May 2023

Volume 184, In Progress

Breast cancer

Pembrolizumab in combination with nab-paclitaxel for the treatment of patients with early-stage triple-negative breast cancer – A single-arm phase II trial (NeoImmunoboost, AGO-B-041)

OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial

Clinical efficacy of fulvestrant versus exemestane as first-line therapies for Chinese postmenopausal oestrogen-receptor positive /human epidermal growth factor receptor 2 -advanced breast cancer (FRIEND study)

Lung cancer

Multicentre real-world data of ramucirumab plus docetaxel after combined platinum-based chemotherapy with programmed death-1 blockade in advanced non-small cell lung cancer: NEJ051 (REACTIVE study)

Adjuvant durvalumab after concurrent chemoradiotherapy for patients with unresectable stage III NSCLC harbouring uncommon genomic alterations

Gastrointestinal oncology

Soluble programmed cell death ligand 1 predicts prognosis for gastric cancer patients treated with nivolumab: Blood-based biomarker analysis for the DELIVER trial

Primary tumour side as a driver for treatment choice in RAS wild-type metastatic colorectal cancer patients: a systematic review and pooled analysis of randomised trials

Clinical and exploratory biomarker findings from the MODUL trial (Cohorts 1, 3 and 4) of biomarker-driven maintenance therapy for metastatic colorectal cancer

Head and neck oncology

Proton pump inhibitors and antibiotics adversely effect the efficacy of nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

Quality of life

Impact of immune checkpoint inhibitors and targeted therapy on health-related quality of life of people with stage III and IV melanoma: a mixed-methods systematic review

Epidemiology and prevention

Faecal haemoglobin concentration predicts all-cause mortality

Tumour Immunology and Immunotherapy

Immunogenetic variations predict immune-related adverse events for PD-1/PD-L1 inhibitors

Survival and immunotoxicities in association with sex-specific body composition patterns of cancer patients undergoing immune-checkpoint inhibitor therapy – A systematic review and meta-analysis

Biomarkers of response to immunotherapy in early stage non-small cell lung cancer

Correspondence

Letter Re: Metabolic switch in cancer – Survival of the fittest

Targeting metabolic pathways in cancer: A double-edged sword?

The response rate by tumour type for tissue-agnostic approved drugs

eIF4F translation initiation complex, a predictive marker of response to immunotherapy in mucosal melanoma